Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

18.03.2020 | short review | Ausgabe 2/2020 Open Access

memo - Magazine of European Medical Oncology 2/2020

ESMO 2019: breast cancer

memo - Magazine of European Medical Oncology > Ausgabe 2/2020
Rupert Bartsch
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


This articles reviews results of relevant breast cancer trials presented at the 2019 ESMO Meeting. In triple-negative disease, addition of pembrolizumab to standard neoadjuvant chemotherapy yielded a pathologic complete response (pCR) rate of 64.8%, the highest pCR rate reported to date in this setting; in addition, a trend towards improved event-free survival was observed in the immunotherapy group. In pretreated patients with metastatic triple-negative breast cancer, single-agent pembrolizumab was not superior to conventional chemotherapy. In metastatic hormone-receptor positive disease, an update of the MONARCH2 and MonaLEEsa‑3 studies indicated an overall-survival benefit in favour of the respective CDK4/6 inhibitor groups emphasizing the clinical importance of this class of drugs.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 2/2020

memo - Magazine of European Medical Oncology 2/2020 Zur Ausgabe